Akut miyeloid lösemide kemik iliğinde B lenfosit sayısının remisyon durumu ile ilişkisi, retrospektif çalışma
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tekirdağ Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu tez çalışmasında 2015 – 2021 yılları arasında Tekirdağ Namık Kemal Üniversitesi Hastanesi'ne başvuran Akut Miyeloid Lösemi (AML) tanısı almış olan 87 hastanın kemik iliği aspirasyonlarındaki B lenfosit sayısının remisyon durumu ile ilişkisi retrospektif olarak incelenmiştir. AML, hematopoez aşamasında farklılaşmanın durması ve blast hücre popülasyonundaki artış ile karakterize bir neoplazmdır. Ortalama tanı yaşı 67 olup, erkek bireylerde kadınlara oranla daha sık görülmektedir. Humoral immün sistemdeki B lenfositlerin T lenfositler ile birlikte kanser ve lösemi hücrelerinin ortadan kaldırılmasında rol oynadığı düşünülmektedir. Çalışmamızda AML tanısı almış 87 hastanın demografik verileri, AML tipi, genetik analizleri, kan sayımı değerleri, LDH, ürik asit değerleri, mutlak lenfosit, mutlak CD19 değerleri, tanı anı akım sitometrideki lenfosit, blast, CD19 oranları, nakil durumları değerlendirildi. Olgularımızın %50,6'sının kadın, %49,4'ünün erkek olduğu ve %71,3'ünün ex, %28,7'sinin ise yaşadığı belirlendi. Tanı anındaki yaş ortalaması 56,93 ± 15,19 yıl idi. ELN sitogenetik risk sınıflandırılmasına göre %25,3 hasta iyi risk grubu, %43,7 hasta orta risk grubu ve %26,4 hasta kötü risk grubuna dahildi. Hematopoietik kök hücre nakli olan %20,7 hasta mevcut idi. Sağkalım üzerine etkiler istatistiksel olarak değerlendirildiğinde tanı anındaki yaş ve ELN risk grubunun etkisi anlamlı saptandı, CD19'un sağkalım üzerinde etkisinde anlamlı fark saptanmadı. Remisyon durumuna etki edenler arasında yaş, ELN risk grubu, nakil durumu, sağkalım, ürik asidin anlamlı olduğu saptandı. Tanı anı akım sitometrideki CD19'un istatistiksel olarak sınırda anlamlı olduğu saptandı. Çalışmamız AML vakaları için prognostik faktörlerin belirlenmesi ve CD19'un remisyon üzerindeki etkisinin incelenmesi ile literatüre katkı sağlamaktadır. Anahtar Kelimeler: AML, CD19, Akım Sitometri, B Lenfosit, Sağkalım, İmmünfenotipleme.
In this thesis study, the relationship between the number of B lymphocytes in bone marrow aspirations and the remission status of 87 patients diagnosed with Acute Myeloid Leukemia (AML) who applied to Tekirdağ Namık Kemal University Hospital between 2015 and 2021 was examined retrospectively. AML is a neoplasm characterized by cessation of differentiation at the stage of hematopoiesis and an increase in the blast cell population. The mean age at diagnosis is 67, and it is more common in males than females. B lymphocytes in the humoral immune system are thought to play a role in the elimination of cancer and leukemia cells together with T lymphocytes. In our study, demographic data, AML type, genetic analysis, blood count values, LDH, uric acid values, absolute lymphocyte, absolute CD19 values, lymphocyte, blast, CD19 ratios in flow cytometry at the time of diagnosis, and transplantation status of 87 patients diagnosed with AML were evaluated. It was determined that 50.6% of our cases were female, 49.4% were male, and 71.3% were ex and 28.7% were alive. The mean age at diagnosis was 56.93 ± 15.19 years. According to ELN cytogenetic risk classification, 25.3% of patients were in the good risk group, 43.7% in the intermediate risk group, and 26.4% in the bad risk group. There were 20.7% patients who had hematopoietic stem cell transplantation. When the effects on survival were evaluated statistically, the effect of age at diagnosis and ELN risk group was found to be significant, but no significant difference was found in the effect of CD19 on survival. Age, ELN risk group, transplant status, survival, and uric acid were found to be significant among those affecting remission status. CD19 in flow cytometry at the time of diagnosis was found to be statistically significant at the border. Our study contributes to the literature by determining the prognostic factors for AML cases and examining the effect of CD19 on remission. Key words: AML, CD19, Flow Cytometry, B Lymphocyte, Mortality, Immunophenotyping
In this thesis study, the relationship between the number of B lymphocytes in bone marrow aspirations and the remission status of 87 patients diagnosed with Acute Myeloid Leukemia (AML) who applied to Tekirdağ Namık Kemal University Hospital between 2015 and 2021 was examined retrospectively. AML is a neoplasm characterized by cessation of differentiation at the stage of hematopoiesis and an increase in the blast cell population. The mean age at diagnosis is 67, and it is more common in males than females. B lymphocytes in the humoral immune system are thought to play a role in the elimination of cancer and leukemia cells together with T lymphocytes. In our study, demographic data, AML type, genetic analysis, blood count values, LDH, uric acid values, absolute lymphocyte, absolute CD19 values, lymphocyte, blast, CD19 ratios in flow cytometry at the time of diagnosis, and transplantation status of 87 patients diagnosed with AML were evaluated. It was determined that 50.6% of our cases were female, 49.4% were male, and 71.3% were ex and 28.7% were alive. The mean age at diagnosis was 56.93 ± 15.19 years. According to ELN cytogenetic risk classification, 25.3% of patients were in the good risk group, 43.7% in the intermediate risk group, and 26.4% in the bad risk group. There were 20.7% patients who had hematopoietic stem cell transplantation. When the effects on survival were evaluated statistically, the effect of age at diagnosis and ELN risk group was found to be significant, but no significant difference was found in the effect of CD19 on survival. Age, ELN risk group, transplant status, survival, and uric acid were found to be significant among those affecting remission status. CD19 in flow cytometry at the time of diagnosis was found to be statistically significant at the border. Our study contributes to the literature by determining the prognostic factors for AML cases and examining the effect of CD19 on remission. Key words: AML, CD19, Flow Cytometry, B Lymphocyte, Mortality, Immunophenotyping
Açıklama
Sağlık Bilimleri Enstitüsü, Tümör Biyolojisi ve İmmünolojisi Ana Bilim Dalı
Anahtar Kelimeler
Biyoloji, Biology
